- 01A raised PSA is a leak signal
PSA rises whenever the prostate leaks more of it into the blood, from enlargement, inflammation, a recent trigger or cancer. The number says something is happening in the prostate; the repeat test, free PSA, MRI and biopsy say what.
- 02The cut-off is a sliding scale
Cancer was found in 6.6% of men with PSA under 0.5 ng/mL and 26.9% at 3.1 to 4.0 ng/mL in the Prostate Cancer Prevention Trial, so 4.0 ng/mL is one point on a rising slope of risk.
PSA (prostate-specific antigen) is a protein made by the prostate gland, and a small amount always leaks into the blood. A high result means more is leaking than expected for your age: it tells you something is going on in the prostate, but it cannot say what. Enlargement, inflammation, a recent ride or ejaculation and cancer can all push the number up, so the first job is to rule out the temporary causes and repeat the test under clean conditions. For what the test measures and the full normal ranges, see the main total PSA (tPSA) page; this page covers what a raised number means and what usually comes next.
What counts as high
Most US labs flag total PSA above 4.0 ng/mL. The units ng/mL and µg/L give the same number, so 4.0 ng/mL is 4.0 µg/L on a UK or European report (how lab units work). The 4.0 line is blunt. PSA rises with age as the prostate grows, so a PSA of 3.8 ng/mL means something different at 45 than at 75.
Where an example PSA of 5.2 ng/mL sitsng/mL
In 1993, Oesterling and colleagues measured PSA in a community sample of healthy men in Olmsted County, Minnesota, and set an upper limit for each decade of age 3. Many labs and reading tools still use these limits.
| Age | Age-specific upper limit (ng/mL) | Same limit in µg/L | Above this reads as |
|---|---|---|---|
| 40 to 49 | 2.5 | 2.5 | High for age |
| 50 to 59 | 3.5 | 3.5 | High for age |
| 60 to 69 | 4.5 | 4.5 | High for age |
| 70 to 79 | 6.5 | 6.5 | High for age |
The Oesterling limits came from a mostly white group of men, so they may sit too high for men at higher risk. The AUA/SUO guideline (from the American Urological Association and the Society of Urologic Oncology) treats Black ancestry, inherited mutations such as BRCA2 and a strong family history as higher risk, and suggests a first PSA at 40 to 45 for those men instead of 45 to 50 2. No guideline grades PSA in multiples of the upper limit the way liver enzymes are graded. The useful scale for PSA is the chance of finding cancer at each level.
How likely is cancer at your number
The Prostate Cancer Prevention Trial biopsied men whose PSA had stayed at or below 4.0 ng/mL for seven years, so it shows what sits under the line most people treat as safe 4. Cancer turned up at every level, and the share rose steadily with PSA.
| PSA (ng/mL) | Chance of cancer on biopsy | Source |
|---|---|---|
| 0 to 0.5 | 6.6% | Prostate Cancer Prevention Trial 4 |
| 0.6 to 1.0 | 10.1% | Prostate Cancer Prevention Trial 4 |
| 1.1 to 2.0 | 17.0% | Prostate Cancer Prevention Trial 4 |
| 2.1 to 3.0 | 23.9% | Prostate Cancer Prevention Trial 4 |
| 3.1 to 4.0 | 26.9% | Prostate Cancer Prevention Trial 4 |
| Above 4.0, biopsied for a raised PSA | About 25% | National Cancer Institute 1 |
When it is urgent
When to get help now
PSA has no lab critical value. Urgency comes from symptoms, and any PSA level with one of these changes the timeline.
- You cannot pass urine, or only a dribble, with a swollen, painful lower belly: emergency care now.
- Fever, chills or shaking with painful or burning urination: same-day care, since an acute prostate infection can make you very unwell and pushes PSA far above the limit.
- Severe pain in the pelvis, between the legs or in the back passage with a fever: same-day care.
- Blood in your urine or semen: see a clinician within days.
- New bone or back pain, or weight loss you cannot explain, alongside a raised PSA: book a prompt appointment and mention the PSA result.
- A PSA that has climbed while on testosterone therapy: tell the prescriber before the next review is due.
LifeFrom can't examine you or assess a symptom. If something feels seriously wrong, trust that and get care rather than waiting on a test.
Is it really high?
A single raised PSA often has an everyday explanation. The National Cancer Institute names ejaculation, vigorous exercise such as cycling, prostate infection or inflammation, a recent prostate biopsy and drugs such as finasteride among the things that move PSA 1. Check each one against the day of your draw before reading anything into the number.
| What happened | Effect on PSA | How long it lasts | Before the retest |
|---|---|---|---|
| Ejaculation in the 2 days before the draw | Small rise | About 2 days | Avoid ejaculation for 2 days 1 |
| Long cycling or other vigorous exercise | Small rise | About 2 days | Rest for 2 days (exercise before a blood test) 1 |
| Prostate infection or prostatitis (inflammation of the prostate) | Can be large | A month or two 1 | Retest once it has cleared, at a time your clinician sets 1 |
| Prostate biopsy | Can be large | A month or two 1 | Ask the team that did the procedure how long to wait; the same goes for a catheter or cystoscopy (a camera into the bladder) |
| Finasteride or dutasteride | Lowers PSA by about half in the first 12 months | As long as you take it | Clinicians adjust the measured value upward, roughly doubling it 8 |
| Testosterone therapy | Modest rise, mostly in the first months | While on therapy | See the testosterone section below 7 |
| A different lab | Assays read slightly differently | Every test | Retest at the same lab |
Finasteride and dutasteride (5-alpha reductase inhibitors, prescribed for an enlarged prostate or hair loss) block the conversion of testosterone to DHT, and the prostate shrinks and makes less PSA. Finasteride cuts PSA by about 50% in the first 12 months, and in the Prostate Cancer Prevention Trial the factor needed to correct for it rose from 2 at two years to 2.5 at seven years 8. A PSA of 2.5 ng/mL after two years on finasteride therefore reads roughly like 5.0 ng/mL.
For people with a newly elevated PSA, clinicians should repeat the PSA prior to a secondary biomarker, imaging, or biopsy.AUA/SUO Early Detection of Prostate Cancer guideline, 2023 2
The repeat earns its place. In 972 men who gave a blood sample once a year for four years, 44% of those with a PSA above 4 ng/mL had a normal value on at least one later test 5. The authors concluded that a single raised PSA should be confirmed several weeks later before biopsy. The National Cancer Institute notes that a doctor may repeat an abnormal screening PSA in about 6 to 8 weeks in a man with no symptoms 1.
Causes
What raises PSA, most likely first
Each cause has a clue that points to it and a test that confirms it. Prostate cancer comes last because it is the least common explanation for a single raised PSA; it still has to be ruled out.
- 01Enlarged prostate (BPH)
BPH (benign prostatic hyperplasia) is non-cancer growth of the gland; a bigger prostate releases more PSA 1. Clue: a weak stream, getting up at night to urinate, a large gland on exam. Confirmed by exam and imaging, with free PSA as a pointer.
- Free/total PSA ratio
- A higher free share leans toward BPH
- 02Prostatitis or urinary infection
Inflammation or infection of the prostate lets more PSA leak into the blood, for a month or two 1. Clue: burning, fever, pelvic or perineal pain. Confirmed by urine tests; fever with painful urination needs same-day care.
- White cells in urine
- Raised in infection
- 03
- 04Testosterone therapy
Restoring testosterone in men with low levels raises PSA modestly, mostly in the first months 7. Clue: the rise follows the start of treatment. Confirmed by the testosterone level and a repeat PSA against the Endocrine Society thresholds.
- Total testosterone
- Shows the dose effect
- 05Prostate cancer (must not miss)
Cancer disrupts the gland's structure so more PSA reaches the blood; about 1 in 4 men biopsied for a raised PSA have it 1. Clue: a PSA that stays raised on repeat, a low free share, a hard area on exam. Confirmed by MRI and biopsy. Early cancer is usually silent; new bone pain or weight loss with a high PSA needs a prompt appointment.
- Free PSA
- A lower free share leans toward cancer
These are things a symptom like this can be linked with, not a diagnosis. Several can sit together, and a clinician who knows your history puts them in order for you.
Symptoms
PSA causes no symptoms at any level. Any symptoms come from whatever is raising it. Urinary symptoms such as a weak stream, urgency or getting up at night (see frequent urination) point toward an enlarged prostate, but they do not rule cancer in or out, because early prostate cancer usually causes no symptoms, which is why screening is aimed at men without them 1. Fever, burning and pelvic pain point toward infection. A raised PSA does not cause tiredness or erection problems, so if those are present they need their own explanation.
Read it with your other markers
Markers that sort the causes of a high PSA
| Pattern | What it suggests | Read more |
|---|---|---|
| Total PSA 4 to 10, free PSA above 25% | Leans toward an enlarged prostate 9 | Free/total PSA ratio |
| Total PSA 4 to 10, free PSA 25% or lower | Higher chance of cancer; more work-up likely 9 | Free PSA |
| Raised PSA plus white cells in urine | Infection or prostatitis | High white cells in urine |
| PSA up after starting testosterone | Therapy effect, checked against Endocrine Society thresholds 7 | TRT blood work |
| PSA lower than expected on finasteride | Masked value; roughly doubled to read it 8 | DHT |
High PSA on testosterone therapy
The Endocrine Society guideline asks for a baseline PSA before testosterone therapy starts and a check 3 to 12 months in. It advises a urology review if PSA rises by more than 1.4 ng/mL within 12 months, if a confirmed PSA is above 4.0 ng/mL, or if the prostate exam is abnormal 7. A smaller rise is usually read as a therapy effect, judged against your own starting value. Any change to the dose or stopping is a decision for the prescriber; see TRT blood work for the full monitoring schedule.
What usually happens next
From a high PSA to an answer
| Test | What it adds | What it cannot tell you |
|---|---|---|
| Repeat total PSA | Shows whether the first rise was temporary 5 | Why PSA is raised |
| Free PSA percentage | In the 4 to 10 range, a 25% cut-off caught 95% of cancers and spared 20% of needless biopsies 9 | Whether a cancer is aggressive |
| PHI or 4Kscore | A combined blood score for the chance of significant cancer 2 | Where in the gland a cancer sits |
| PSA density | Separates a big benign gland from a small gland making too much PSA | Anything without a measured prostate volume |
| MRI | Finds and grades suspicious areas; can avoid a biopsy 6 | A firm diagnosis on its own |
| Biopsy | The diagnosis and the grade | Cancer outside the sampled areas |
A PSA that creeps up
PSA velocity is how fast PSA rises per year, and doubling time is how long it takes to double. Both can mislead, because PSA moves between draws in healthy men: the Eastham study measured this year-to-year fluctuation directly 5. The AUA/SUO guideline says velocity should not be the sole reason for further biomarkers, imaging or biopsy 2. A steady rise across three or more tests from the same lab, under the same prep, tells a clinician far more than two numbers a year apart; why trends beat single readings explains the logic.
What can bring it down
The goal of a follow-up is to find the cause, because a lower number on its own changes nothing about risk. These are the changes with real human evidence on PSA.
| Change | Effect on PSA in humans | Evidence | Source |
|---|---|---|---|
| 2 days without ejaculation or vigorous exercise before the draw | Removes a temporary rise | Guideline advice | NCI 1 |
| Treating a confirmed infection or prostatitis | PSA falls back as the inflammation settles | Guideline advice | NCI 1 |
| Finasteride or dutasteride, prescribed for BPH or hair loss | About 50% lower in the first 12 months; cancer risk is not removed, so the value is adjusted upward to read it | RCT | Etzioni 2005 8 |
Supplements sold for prostate health, such as saw palmetto, and diet changes have no trial evidence of lowering PSA in a way that changes cancer risk. How supplements affect blood tests covers the ones that do shift lab values.
Free, no accountRead your blood testHave the full report, or PSA results from two different dates? Read every marker on it free, and see whether a move is wobble or a clear rise.Read my results
Who gets tested and when
The AUA/SUO guideline suggests offering a baseline PSA at 45 to 50, and at 40 to 45 for men with Black ancestry, an inherited mutation such as BRCA2 or a strong family history 2. Screening finds cancers that would never have caused harm as well as ones that would, so the decision to test is a shared one with your clinician. For where PSA fits among other cancer blood tests, see tumor markers explained and blood tests for men.
Citations
- National Cancer Institute. Prostate-Specific Antigen (PSA) Test fact sheet.
- Wei JT et al. Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. J Urol 2023;210:46-53.
- Oesterling JE et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993;270:860-4.
- Thompson IM et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.
- Eastham JA et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 2003;289:2695-2700.
- Kasivisvanathan V et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis (PRECISION). N Engl J Med 2018;378:1767-77.
- Bhasin S et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018;103:1715-44.
- Etzioni RD et al. Long-term effects of finasteride on prostate specific antigen levels: results from the Prostate Cancer Prevention Trial. J Urol 2005;174:877-81.
- Catalona WJ et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542-7.
Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.



